

**21-JUL-2017 18:10
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST	LAST	LAST	LAST	LAST	
			Month	Month	Month	Month	Month	Month	
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1 Y 1	Recurrence Score testing	9252	799	420	203	68	16	BREAST
			9252	799	420	203	68	16	
	2 Y 2	Chemo and Endocrine Therapy	2493	272	138	71	22	6	
		3 Endocrine Therapy Alone	2483	276	145	71	21	7	
			4976	548	283	142	43	13	
S1207-Brst,Adj,Endocrine+/-Everolimus	1 Y 1	Blinded drug + Endocrine	647	222	114	53	18	7	BREAST
		2 Blinded drug + Endocrine	641	213	111	50	17	4	
			1288	435	225	103	35	11	
S1316-Compar. Effectiv. Trial for MBO	1 Y 1	Randomization: Surgery	1	0	0	0	0	0	SURV
		2 Randomization: Non-surgical M	1	1	1	1	0	0	
		3 Patient Choice: Surgery	29	19	11	6	1	0	
		4 Patient Choice: Non-surgical M	61	36	23	12	2	0	
			92	56	35	19	3	0	
S1400I-Non-Match: Nivo + Ipi vs Nivo	1 Y 1	Nivolumab + Ipilimumab	103	64	22	10	2	1	LUNG
		2 Nivolumab	108	72	29	13	4	1	
			211	136	51	23	6	2	
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	1 Y 1	Tissue for PD-L1 testing	1302	1024	538	254	94	24	MELAN
			1302	1024	538	254	94	24	
	2 Y 2	FDA approved regimen	605	483	267	126	48	15	
		3 MK-3475 (Pembrolizumab)	589	474	249	115	40	8	
			1194	957	516	241	88	23	
S1415CD-TrACER CSF Standing Order Intervention for FN	1 Y 1	Site assigned to Cohort	259	259	197	99	34	8	CCD
		2 Site randomized: Control	128	128	123	75	33	8	
		3 SiteRand Int Risk: CSF	152	152	134	75	28	6	
		4 SiteRand Int Risk: No CSF	100	100	93	66	17	2	
			639	639	547	315	112	24	
S1417CD-Colorectal, Cost Cohort Study	1 Y 1	Observation	75	72	57	35	12	0	CCD
			75	72	57	35	12	0	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1 Y 1	Tissue for PD-L1 testing	49	49	47	32	11	2	BREAST
			49	49	47	32	11	2	

21-JUL-2017 18:10
CANCER CONTROL ACCRUAL REPORT

STUDY	O R E G I S T R A T I O N	P E R I O D	A R M	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
				REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS	
	2	Y	2	Observation	22	22	22	18	6	3
	3			MK-3475 (Pembrolizumab)	19	19	19	13	3	1
					41	41	41	31	9	4
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y	1	TICE BCG	5	5	5	3	1	0 GU
	2			Tokyo-172 BCG	4	4	4	3	1	1
	3			Prime + Tokyo-172 BCG	4	4	4	3	1	1
					13	13	13	9	3	2
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0	Y	0	Pre-Registration	376	139	61	34	16	7 PREV
					376	139	61	34	16	7
	1	Y	1	Blinded drug	42	18	10	7	0	0
	2			Blinded drug	36	12	6	0	0	0
	3			Blinded drug	35	12	4	0	0	0
	4			Blinded drug	41	16	12	6	1	0
					154	58	32	13	1	0